We demonstrate a physiological role for tumstatin, a cleavage fragment of the ␣3 chain of type IV collagen (Col IV␣3), which is present in the circulation. Mice with a genetic deletion of Col IV␣3 show accelerated tumor growth associated with enhanced pathological angiogenesis, while angiogenesis associated with development and tissue repair are unaffected. Supplementing Col IV␣3-deficient mice with recombinant tumstatin to a normal physiological concentration abolishes the increased rate of tumor growth. The suppressive effects of tumstatin require ␣V␤3 integrin expressed on pathological, but not on physiological, angiogenic blood vessels. Mice deficient in matrix metalloproteinase-9, which cleaves tumstatin efficiently from Col IV␣3, have decreased circulating tumstatin and accelerated growth of tumor. These results indicate that MMP-generated fragments of basement membrane collagen can have endogenous function as integrin-mediated suppressors of pathologic angiogenesis and tumor growth.
Introduction
quential VBM changes that result in exposure of endothelial cells to different isoforms, degradation products, and molecular Vascular basement membranes (VBM) are specialized extracelstructures of VBM molecules in a short period of time (Carmeliet lular matrices that provide mechanical support for endothelial and Jain, 2000; Czubayko et al., 1997; Eliceiri et al., 1999; cells (Colorado et al., 2000; Madri, 1997; Paulsson, 1992; Timpl, Ferrara, 2000; Folkman, 2001; Folkman and Kalluri, 2003; Hana-1996; Yurchenco and O'Rear, 1994) and influence cellular behan and Weinberg, 2000; Kalluri, 2003; Padera et al., 2002 ; havior such as differentiation and proliferation (Madri, 1997; Stacker et al., 2002) . Paulsson, 1992; Tsilibary et al., 1990) , especially during the Our prevailing hypothesis is that such sequential isoform sprouting of new capillaries. VBM organization is dependent on switching and structural changes associated with VBM can prothe assembly of a type IV collagen network, which is believed vide crucial angiogenic and antiangiogenic stimuli to perpetuate to occur via the C-terminal globular non-collagenous (NC1) doformation of new capillaries (Colorado et al., 2000 ; Kamphaus main of Col IV (Kuhn, 1995; Madri, 1997; Madri and Pratt, 1986; Maeshima et al., 2000a , 2000b , 2001a , 2001b , Timpl, 1996 Tsilibary et al., 1990; Zeisberg et al., 2001; Zhang et 2002; Thyboll et al., 2002) . There are six distinct gene products, al., 1994) . Inhibitors of collagen metabolism have antiangiogenic ␣1-␣6 for Col IV Prockop and Kivirikko, 1995) . The distribution of the ␣3 (IV) chain is limited to glomerular properties, supporting the notion that basement membrane (BM) collagen synthesis and deposition are crucial for blood BM (GBM), several BM of the cochlea, ocular BM of the anterior lens capsule, Descemet's membrane, ovarian and testicular BM vessel formation and survival (Maragoudakis et al., 1993 (Maragoudakis et al., , 1995 Tsilibary et al., 1990) . Once the endothelium receives signals (Frojdman et al., 1998) , alveolar capillary BM Kashtan, 1998; Polette et al., 1997) , and the VBM of to proliferate from the tumor microenvironment, it initiates se-several organs (Derry and Pusey, 1994; Kashtan, 1998) , but is To determine if altered vascularity was the underlying mechanism of the increased tumor growth, we analyzed a second absent from epidermal and VBM in the skin (Kashtan, 1998) .
During BM synthesis, turnover fragments are generated type of pathological angiogenesis in the growth factor-supplemented Matrigel plug assay. We observed increased angiogenwhich are liberated into the circulation, raising the question as to whether they have any physiological function (Hogemann et esis in the Col IV␣3/tumstatin-deficient mice, as compared to the wild-type mice ( Figure 2B ). Col IV␣3/tumstatin-deficient al., 1984; Ortega and Werb, 2002; Standker et al., 1997) . The bioactive NC1 domain of Col IV␣3, called tumstatin, acts as an mice demonstrating increased rate of tumor growth had increased numbers of CD31-positive blood vessels ( Figure 2C ). angiogenesis inhibitor, inhibiting the proliferation of capillary endothelial cells and blood vessel formation in vitro and in vivo Recent studies have suggested that increases in the circulating vascular endothelial growth factor receptor 2 (VEGFR2)-positive (Maeshima et al., 2000a (Maeshima et al., , 2000b (Maeshima et al., , 2001a (Maeshima et al., , 2001b Petitclerc et al., 2000) . Deletion mutagenesis experiments have narrowed the endothelial cells correlate directly with increase in tumor angiogenesis and can serve as in vivo indicators of tumor angiogenbiological activity to a 25 amino acid stretch in the middle of the molecule (Maeshima et al., 2001b) . Tumstatin binds to ␣V␤3 esis Lyden et al., 2001; Monestiroli et al., 2001) . Col IV␣3/tumstatin-deficient mice had increased circulatintegrin via a mechanism independent of the RGD-containing amino acid sequence (Maeshima et al., 2000a) . However, since ing VEGFR2-positive endothelial cells ( Figure 2D ). If the regulation of angiogenesis relies on the presence of previous studies relied on exogenous addition of tumstatin (or fragments of other basement membrane collagens), this raises circulating tumstatin, then exogenous addition of tumstatin to physiological levels in the null mice should decrease the number the question of whether such fragments have an endogenous physiological function. Here we provide genetic evidence supof blood vessels and circulating endothelial cells to the wildtype baseline levels. Indeed, we observed suppression of tumor porting a role for tumstatin as an endogenous suppressor of pathological angiogenesis and tumor growth.
angiogenesis to wild-type levels ( Figures 2C and 2D ), indicating that the lack of tumstatin domain alone is responsible for the accelerated tumor growth in the Col IV␣3-deficient mice.
Results
By contrast, physiological angiogenesis associated with tissue repair was unaffected in the Col IV␣3/tumstatin-deficient Mice with deletion of collagen IV ␣3 (tumstatin precursor) exhibit normal pregnancy, development, and wound mice. Closure/repair in skin wounds progressed at the same rate in the wild-type and the null mice ( Figure 3A ) and showed healing, but accelerated pathologic angiogenesis and tumor growth insignificant differences in histology and CD31-positive blood vessels ( Figures 3A and 3B) . Similarly, regeneration of liver after Angiogenesis plays an important role during pregnancy and embryonic development. Tumstatin, which has a circulating partial hepatectomy was similar in the wild-type and null mice. The rates of regeneration assessed by the proliferation index physiological concentration of about 336 Ϯ 28 ng/ml in normal mice, was absent in mice deficient in ␣3 chain of Col IV, the of the liver, as determined by BrdU staining ( Figure 3C ), and angiogenesis, assessed by the number of von Willebrand Factor precursor for tumstatin ( Figures 1A and 1B) , without altering the litter size, pregnancy, or development ( Figures 1C and 1D) . In (vWF)-positive blood vessels ( Figure 3D ), were similar in the wild-type and null mice. the present study, we refer to the Col IV␣3-deficient mice (Andrews et al., 2002; Cosgrove et al., 1996; Miner and Sanes, 1996) as also tumstatin deficient. After week 20, these mice on Antiangiogenic activity of tumstatin requires ␣V␤3 integrin C57BL/6 background develop kidney dysfunction associated with GBM abnormalities and inflammation and die at around Tumstatin binds to ␣V␤3 integrin in a vitronectin/RGD sequence-independent manner (Maeshima et al., 2000a) . If the week 40 due to renal failure resulting from the absence of Col IV␣3 in the GBM (Andrews et al., 2002; data not shown) .
antiangiogenic action of tumstatin is mediated through this receptor, then cells and mice lacking ␣V␤3 integrin should not Next, we evaluated tumor-associated pathological angiogenesis in Col IV␣3/tumstatin-deficient mice on a C57BL/6 respond to it. Tumstatin or active derivative T7 peptide (Maeshima et al., 2001b) at 1 M, which has been shown previously background. Tumors from Lewis lung carcinoma (LLC) cells (10 6 ) placed on the backs of mice appeared at about 7 days to achieve maximum inhibition of endothelial cell proliferation (Maeshima et al., 2000b) , significantly inhibited proliferation of and grew at the same rate in wild-type and Col IV␣3/tumstatindeficient mice until they reached about 500 mm 3 of tumor volwild-type mouse lung endothelial cells (MLEC) in response to growth factor stimulation, while proliferation of ␤3 integrin null ume ( Figure 2A ). Consistently, from this size, the tumors on Col IV␣3/tumstatin-deficient mice grew at a faster rate and, by day MLEC was unaffected ( Figure 4A ). By contrast, mouse endostatin (the NC1 domain of ␣1 chain of collagen XVIII) was equally 26, the tumors on the Col IV␣3/tumstatin-deficient mice were more than twice the size of wild-type tumors (Figure 2A ). Admineffective in inhibiting the proliferation of both wild-type and ␤3 integrin null MLEC ( Figure 4A ). istration of 300 ng of recombinant human tumstatin, which has a half-life of about 20 hr in mice (data not shown), daily to the Neovascularization of growth factor-supplemented Matrigel plugs in mice is associated with significant expression of ␤3 Col IV␣3/tumstatin-deficient mice with 500 mm 3 LLC tumors, decreased tumor growth to wild-type levels ( Figure 2A ). These integrin ( Figure 4B ). We next evaluated the antiangiogenic activity of tumstatin in vivo in the Matrigel plug assay system in experiments demonstrate that restoration of physiological levels of tumstatin in Col IV␣3/tumstatin-deficient mice suppresses wild-type and ␤3 integrin-deficient mice on the C57BL/6 background. Both tumstatin and endostatin significantly inhibited the accelerated growth of tumors ( Figure 2A ). Similar results were obtained with syngeneic B16F10 melanoma and T241 VEGF-induced neovascularization of the plugs in the wild-type mice ( Figure 4C ). However, while endostatin significantly inhibfibrosarcoma tumors (O'Reilly et al., 1997) in Col IV␣3/tumstatindeficient mice (data not shown).
ited blood vessels in the Matrigel plugs implanted in the ␤3 integrin-deficient mice, tumstatin had an insignificant effect (Fig- this issue, we assessed the vascular expression of ␤1 and ␤3 integrin in tumors starting from a size of 100 mm 3 to 5000 mm 3 . ure 4C). These data suggest that tumstatin action in vivo is likely mediated by ␣V␤3 integrins.
Interestingly, our results indicate that while ␤1 was expressed in about 80% of the blood vessels even in tumors as small as 100 mm 3 , ␤3 integrin was expressed in only about 8% of Tumstatin functions as an inhibitor of tumor-associated pathological angiogenesis, while having no effect capillaries at this stage ( Figure 6 ). The ␤3 expression increased to about 40% of the blood vessels by the time the tumors on physiological angiogenesis due to differential expression of ␤3 integrin reached 500 mm 3 and remained at that level, no matter how How can tumstatin function as an inhibitor of tumor-associated large the tumor ( Figure 6 ). Expression of ␤1 integrin at this stage pathological angiogenesis, while having no effect on physiologicontinued to be detected in 80% of the blood vessels. Since cal angiogenesis associated with repair and regeneration of skin significant ␤3 integrin expression on the vasculature was seen and liver? Our experiments suggest that tumstatin depends on only beginning at the size of 500 mm 3 and tumstatin does not ␣V␤3 integrin for inhibition of tumor-associated pathological induce negative regulation when the tumors are smaller than angiogenesis. We detected ␣V␤3 integrin on about 40% of the 500 mm 3 (Figures 2, 4, 5 and 6), the vascular expression pattern blood vessels and small capillaries in proliferating tumors; howof ␤3 integrin provides a possible explanation for the lack of ever, we did not detect it in the blood vessels of healing skin tumor growth difference between the wild-type and Col IV␣3/ wounds or regenerating livers ( Figure 5A ). In contrast, ␤1 integrin tumstatin-deficient mice until the tumors reach the size of was detected on all blood vessels and capillaries associated 500 mm 3 . with tumor growth, healing wounds, and regenerating skin liver ( Figure 5B ). Such differences in ␣V␤3 integrin levels may explain Degradation of basement membrane type IV collagen by MMP-9 generates tumstatin the lack of tumstatin effect on repair and regeneration, while targeting tumor vasculature ( Figure 3 ).
How is tumstatin generated from BM collagen? BM-degrading MMPs that degrade Col IV could potentially liberate fragments Why do tumors grow faster in the Col IV␣3/tumstatin-deficient mice only after they reach a size of 500 mm Matrisian, 2001). We found that active MMP-9 was most effecpared with 350 Ϯ 24 ng/ml in the wild-type mice (p Ͻ 0.01). These results suggest that normal physiological turnover of BM tive in liberating C-terminal NC1 globular domains in dimeric and monomeric forms, detected in the supernatant by polyclonal by MMPs, especially MMP-9, contributes to the circulating levels of tumstatin. tumstatin antibody, from the GBM which is rich in the Col IV␣3 chain (Frojdman et al., 1998; Gunwar et al., 1991; Kalluri and Cosgrove, 2000) (Figures 7A and 7B ). Three other BM-degrading
Restoration of tumstatin levels inhibits the increased tumor growth rate in MMP-9-deficient mice proteinases, MMP-2, MMP-3, and MMP-13, also released tumstatin, but were significantly less efficient (data not shown). What circulating levels of tumstatin are required to inhibit tumor growth? The growth of LLC tumors implanted into wild-type is significantly less efficient in liberating arresten and canstatin from BMs, when compared to tumstatin (data not shown).
mice and MMP-9-deficient mice on a C57BL/6 background was similar until the tumors reached 500 mm 3 , but after that, the Mice deficient in MMP-9 had significantly decreased circulating blood concentrations of tumstatin; 141 Ϯ 21 ng/ml, comtumors on MMP-9-deficient mice exhibited accelerated growth A: Proliferation assay in ␤3 integrin Ϫ/Ϫ endothelial cells. MLEC were isolated from wild-type (␤3 ϩ/ϩ ) and ␤3 integrin Ϫ/Ϫ (␤3 Ϫ/Ϫ ) mice as previously described (Maeshima et al., 2002) . Proliferation was assessed by [ 3 H]-thymidine incorporation. All groups represent triplicate analyses. The results are shown as the mean Ϯ SEM. ** indicates p Ͻ 0.01; compared to control cells. B: Expression of ␤1 and ␤3 integrins in blood vessels of Matrigel plug. ␤1 and ␤3 integrin-positive blood vessels are indicated with arrows. Scale bar: 50 m. C: Matrigel plug assay in ␤3 integrin Ϫ/Ϫ mice. Sections of each Matrigel plug were stained with HE and the number of blood vessels (arrow) was counted. Each column represents the mean Ϯ SEM of 2-4 mice in each group. Data are representative of two independent Matrigel plug experiments. ** indicates p Ͻ 0.01; compared to each control groups. † indicates p Ͻ 0.05; compared to the control group in ␤3 integrin ϩ/ϩ mice. Scale bar: 50 m.
( Figure 8A ). Injection of 200 ng of recombinant human tumstatin strated that tumstatin, a BM Col IV␣3 chain-derived NC1 domain, can be detected in the circulation of normal mice and intravenously daily for 14 days into MMP-9-deficient mice with established tumors raised the concentration of tumstatin to the functions as an endogenous regulator of pathologic angiogenesis and that the activity of tumstatin is dependent on ␣V␤3 normal levels of about 342 Ϯ 13 ng/ml (data not shown) and resulted in a retarded rate of growth to match the wild-type integrin and the ECM-degrading enzyme, MMP-9. The Col IV␣3 chain is localized to many VBM and is most tumor growth ( Figure 8A , inset). This deceleration of tumor growth was accompanied by decreased numbers of CD31-abundant in the GBM of the kidney and the BM of the testis (Frojdman et al., 1998; Hudson et al., 1993; Kahsai et al., 1997) . positive blood vessels and VEGFR2-positive circulating endothelial cells ( Figures 8B and 8C) . Collectively, these results sugIt is likely that physiological turnover of GBM and other BM mediated by ECM-degrading MMPs contributes to the circulatgest that the increase in LLC tumor growth in MMP-9-deficient mice was due to decreased physiological levels of tumstatin.
ing physiological levels of tumstatin. Col IV␣3 chain-deficient mice do not have circulating tumstatin, and syngeneic LLC tumors larger than 500 mm 3 on these mice grew at more than Discussion twice the rate of tumors on wild-type mice. This difference in growth could be restored to wild-type levels when the null mice Basement collagens in their native molecular structure form a scaffold for cell homeostasis. In this study, we have demonwere provided with physiological concentrations of tumstatin in recombinant form. These results suggest that the acceleration of tumor growth in the null mice is not due to the absence of ␣3 (IV) chain, but is likely due the lack of the tumstatin domain. Our study distinguishes the physiological role of tumstatin from tion that, until the tumors reach 500 mm 3 , the difference in tumor growth between the wild-type mice and Col IV␣3/tumstatin-the entire antiangiogenic arsenal including tumstatin is required for the control of tumor growth.
We previously implicated ␣V␤3 integrin as a putative receptor for tumstatin and the binding between them (Maeshima et al., 2000a (Maeshima et al., , 2001a (Maeshima et al., , 2001b (Maeshima et al., , 2002 ) is independent of RGD sequence, vitronectin, and fibronectin binding. In the present study, we used genetic experiments with ␤3-deficient mice to demonstrate that ␣V␤3 integrin mediates tumstatin action. Tumors also grow faster in ␤3-deficient mice than in wild-type mice (Reynolds et al., 2002) . Collectively, these observations strongly suggest a role for ␣V␤3 integrin as a negative regulator of angiogenesis (Hynes, 2002a; Hynes et al., 2002b; Maeshima et al., 2001a) .
Our experiments suggest that tumor angiogenesis, but not angiogenesis associated with the repair of skin wound and regeneration of liver, is associated with robust expression of ␤3 integrins, including ␣V␤3 integrin. This is likely the explanation for the lack of difference on the skin wound repair and liver regeneration in the Col IV␣3/tumstatin-deficient mice and also in pharmacological studies with recombinant human tumstatin (data not shown). Both Col IV␣3/tumstatin-deficient mice and ␤3 integrin-deficient mice on a C57BL/6 background do not exhibit developmental angiogenesis defects (Andrews et al., 2002; Cosgrove et al., 1996; Hodivala-Dilke et al., 1999) , suggesting that ␤3 integrin and tumstatin may not be essential for the regulation of developmental angiogenesis.
MMP-9 has been implicated in the degradation of type IV collagen present in the BM (Egeblad and Werb, 2002; McCawley and Matrisian, 2001) , and fragments of Col IV and laminin have been detected in the serum of normal individuals and cancer patients (Gabrielli et al., 1988; Yudoh et al., 1994) . Tumstatin is a proteolytic product that has to be liberated from the parent Col IV␣3 chain. MMP-9 was the most effective enzyme in the generation of tumstatin domain from BM and type IV collagen amnion. We demonstrated that mice deficient in MMP-9 have A: Western blot of BM degraded by MMP-9. MMP-9 enzyme was added to lower circulating levels of tumstatin, and that this results in GBM at a 1:100; enzyme:substrate ratio, and the generation of tumstatin increased tumor growth. The accelerated tumor growth can be was detected by SDS-PAGE and immunoblotting using anti-tumstatin antirestored to wild-type levels by supplementing the null mice with body. To establish MMP specificity in generation of tumstatin, 20 mM EDTA was added to the MMP/GBM mixture to inactivate MMP. The expected the missing physiological concentration of tumstatin. Moreover, dimer (black arrow) and monomer (white arrow) of tumstatin are indicated.
Col IV is elevated in the tumor tissue and also in the GBM of Monomers and dimers of type IV collagen NC1 domain have been pre-MMP-9-deficient mice (data not shown). Such increased accuviously described (Kalluri et al., 1997b) . mulation is likely due to reduced Col IV turnover in the mice.
B: Quantification of tumstatin production by MMP-9 by ELISA. MMP-9 enzyme was added to 1 mg of GBM, and the production of soluble tumstatin in the These results provide further evidence for the endogenous tusupernatant was analyzed by ELISA using anti-tumstatin antibody. The results mor-suppressive action of tumstatin.
are shown as the mean Ϯ SD. ** indicates p Ͻ 0.01; compared to the control However, MMP-9 has also been implicated as a positive group without enzyme. regulator of the angiogenic switch, which leads to early stage tumor differences resulting in lower tumor size and volume (Bergers et al., 2000) . But, in the same mice at a later stage, the tumor size and volume catch up with the wild-type levels, sugdeficient mice is insignificant. Our results suggest that lack of gesting an acceleration of tumor growth in the absence of significant vascular expression of ␤3 integrin until the tumors MMP-9, as observed in the present study (personal communicareach 500 mm 3 is a likely explanation for the insignificant differtion, G. Bergers and D. Hanahan). In this regard, Pozzi et al. ence in the growth of tumor in the absence of tumstatin before recently demonstrated that pharmacological inhibition of tumors reach 500 mm 3 . Alternatively, it is possible that during MMP-9 in mice results in acceleration of tumor growth, further the early growth phase of the tumors, absence of tumstatin can supporting our observation (Pozzi et al., 2000 (Pozzi et al., , 2002 . Thus, be compensated by other inhibitors of angiogenesis, such as MMP-9 has opposing actions on neoplasia at different stages of thrombospondin-1, angiostatin, and endostatin (Hawighorst et tumor progression. While it may mediate the angiogenic switch al., O'Reilly et al., 1994 O'Reilly et al., , 1997 Rodriguez-Manzaneque leading to the initial burst of tumor growth, it also restrains tumor et al., Volpert et al., 2002) . But once the tumor reaches development by generating endogenous inhibitors of angiogenesis such as tumstatin. After the angiogenic switch has been a critical size and ␤3 integrin expression increases significantly, Ϫ/Ϫ mice. Eight age-and sex-matched MMP-9 Ϫ/Ϫ mice and ten wild-type mice were used for this experiment. While at the very early stages (between 50 mm 3 and 100 mm 3 ), MMP-9 Ϫ/Ϫ tumors grew slightly slower; after that (especially Ͼ500 mm 3 ), they grew at a much faster rate compared to wild-type tumors. Circulating levels of tumstatin were 350 ng/ml in wild-type mice compared to 141 ng/ml in the MMP-9 Ϫ/Ϫ mice. When the tumor volume reached 2.0 cm 3 , tumstatin was intravenously injected into four MMP-9 Ϫ/Ϫ mice (200 ng/day) for 14 days. Their tumor growth was compared to wild-type tumors starting at a size of 2.0 cm 3 . For these experiments, the tumors in the wild-type and MMP-9 Ϫ/Ϫ mice were grown until the both sets of tumors reached 2.0 cm 3 (the wild-type tumors take 28 days to reach this size, while tumors in MMP-9 Ϫ/Ϫ mice take 21 days to reach this size). The accelerated tumor growth in MMP-9 Ϫ/Ϫ mice was suppressed by exogenous tumstatin, when compared with wild-type mice. The results are shown as the mean Ϯ SEM. ** indicates p Ͻ 0.01; * indicates p Ͻ 0.05; compared to wild-type mice. 
In vivo tumor studies
achieved by MMP-9, the degradation products resulting from Age-and sex-matched Col IV␣3/tumstatin Ϫ/Ϫ , MMP-9 Ϫ/Ϫ , and wild-type digestion of BM by the increased amount of MMP-9 negatively (C57BL/6) mice were used for these studies. All mouse studies were reviewed influence the growth of tumors. Therefore, the two opposite and approved by the animal care and use committee of Beth Israel Deaconproperties of MMP-9 are integral to the overall progression of ess Medical Center. Their backs were shaved and LLC cells were injected tumor growth. In this regard, recent clinical trial failures with subcutaneously on the backs of the mice (1 ϫ 10 6 cells/mouse). The tumors were measured using Vernier calipers, and the volume was calculated using MMP inhibitors could be explained by our data, although early a standard formula (Width 2 ϫ Length ϫ 0.52) (Maeshima et al., 2000b) . For intervention of tumor growth by MMP inhibitors is still potentially XV or other molecules in the type XVIII collagen-deficient mice remains to be determined (Eklund et al., 2001 ; Marneros and
Skin wound healing assay
Olsen, 2001).
Excisional (1 cm diameter circular) wounds were made in the epidermis and
In conclusion, this study identifies tumstatin as a physiologidermis of five age-and sex-matched Col IV␣3/tumstatin Ϫ/Ϫ , five Col IV␣3/ cally functional protein domain that circulates in the blood. Tumtumstatin ϩ/Ϫ , and wild-type mice. Two such skin wounds were created on each mouse. The longest and shortest diameters of the wounds were meastatin is not a gene product by itself, but is produced when sured with a Vernier caliper. Areas were calculated, assuming the wounds MMP-9 cleaves it from Col IV in BM. The physiological level were approximate ellipses, using the formula [ X (the longest radius) ϫ (the of tumstatin is dependent on MMP-9, and in its absence, the shortest radius)]. The mice were sacrificed 3 and 10 days after the wound physiological concentration in the blood declines, potentially induction. The wounded tissue and the surrounding area were removed, facilitating pathological angiogenesis and increased growth of fixed in 10% formalin, or snap-frozen in liquid nitrogen and processed for immunohistochemistry.
tumors. The tumor suppressor activity of tumstatin seen at supraphysiological concentrations is associated with inhibition of Liver regeneration study protein synthesis, specifically mediated by mTOR, in the endoSubtotal hepatectomy was performed using Col IV␣3/tumstatin Ϫ/Ϫ, ϩ/Ϫ , and thelial cells (Maeshima et al., 2002) . Based on these results, we wild-type mice under intraperitoneal ketamine (50 mg/kg) (Parke-Davis) anpropose that endogenous inhibitors like tumstatin function as esthesia with five mice in each group. Seventy percent of the total liver tumor suppressors, constituting an additional line of defense mass, including left and middle lobes, was ligated and removed. Ten days after the operation, BrdU (50 mg/kg) was injected intraperitoneally, 2 hr prior against tumor growth in the body, similar to tumor suppressor to sacrifice of the mice. The livers were removed and some parts were genes such as p53.
fixed with 4% paraformaldehyde, and other parts were embedded in OCT compound. BrdU staining was performed using a labeling and detection kit Experimental procedures according to the manufacturer's directions (Roche). BrdU-labeling index was calculated as the number of BrdU-labeled hepatocyte nuclei per 200 Cell lines and knockout mice hepatocyte nuclei, three viewing fields were counted per mouse liver in a Lewis lung carcinoma (LLC) cells were grown at 37ЊC in 5% CO 2 in DMEM blinded fashion. The nuclei were stained with 4Ј, 6-diamidino-2-phenylindole with 10% heat-inactivated fetal bovine serum (FBS) and 5 ng/ml plasmocin (DAPI) (Vector Laboratories, App Imaging). under sterile tissue culture conditions. Primary mouse lung endothelial cells (MLEC) were isolated from 10-to 14-week-old ␤3 integrin Ϫ/Ϫ and wild-type Matrigel plug assay mice. Briefly, MLEC expressing intercellular adhesion molecule-2 (ICAM-2)
In vivo Matrigel plug assay was performed as previously described (Maewere enriched using rat anti-mouse ICAM-2 mAb (Pharmingen) conjugated shima et al., 2000b) . Matrigel (BD Biosciences) was mixed with 20 units/ml to magnetic beads (Dynabeads M-450, Dynal). MLEC were maintained in of heparin (Pierce), 50 ng/ml of vascular endothelial growth factor (R&D), 40% Ham's F-12, 40% DME-Low Glucose, 20% FBS supplemented with and 0.4 M tumstatin or 3 M T7 peptide or 0.5 M endostatin. The Matrigel heparin, endothelial mitogen (Biomedical Technologies, Inc.), glutamine, 100 mixture was injected subcutaneously into 6 Col IV␣3/tumstatin Ϫ/Ϫ , 6 Col units/ml of penicillin, and 100 mg/ml of streptomycin.
IV␣3/tumstatin ϩ/ϩ , 13 ␤3 integrin Ϫ/Ϫ , and 10 integrin ϩ/ϩ mice. Six days after The Col IV␣3 mice were originally described by Miner et al. and Cosgrove the Matrigel mixture injection, mice were sacrificed. The Matrigel plugs were et al. (Cosgrove et al., 1996; Miner and Sanes, 1996) . The mice were procured removed and fixed with 4% paraformaldehyde or 10% formalin. They were from Drs. Sanes, Miner, and Cosgrove and also purchased from the Jackson embedded in paraffin, sectioned, and stained with hematoxylin and eosin laboratories. The mice were backcrossed for more than 15 generations into (HE) or periodic acid-Schiff (PAS). Other parts were embedded in OCT a C57BL/6 background. The ␤3 integrin Ϫ/Ϫ mice were originally described compound. Sections were examined using 10 different fields by light microsby Hodivala- Dilke et al. (Hodivala-Dilke et al., 1999) . The MMP-9 Ϫ/Ϫ mice copy, and the numbers of blood vessels at 200ϫ magnifications were were originally described by Vu et al. (Vu et al., 1998) .
counted and averaged. All sections were coded and observed by an investigator who was blinded for study protocols. Production of recombinant tumstatin and synthetic T7 peptide Recombinant tumstatin was expressed using 293 human embryonic kidImmunostaining ney cells as previously described (Maeshima et al., 2000b) . Synthetic
Immunohistochemical staining was performed as previously described (Ha-TMPFLFCNVNDCNFASRNDYSYWL-T7 peptide (Maeshima et al., 2001b (Maeshima et al., ) mano et al., 2002 . Briefly, 4 m frozen sections were fixed in cold (Ϫ20ЊC) was synthesized at Tufts University Core Facility and analyzed by mass 100% acetone for 3 min then air dried. They were incubated with various primary antibodies, i.e., rat anti-mouse CD31 (Pharmingen), rabbit anti-von spectrophotometric analysis and purified by analytical HPLC.
Willebrand Factor (vWF) (Dako), rat anti-␤1 integrin (Pharmingen), and ham-8-chamber slides. After a 6 hr incubation that allowed endothelial cells to ster anti-␤3 integrin (Pharmingen) antibodies at room temperature for 2 hr.
attach to the slide, the attached cells were stained with anti-VEGFR2 antiSubsequently, they were washed three times in PBS and incubated with body (Santa Cruz). The VEGFR2-positive cells were counted under the fluo-FITC-or tetramethyl rhodamine-conjugated secondary antibodies (Jackson rescence microscope in 10 fields at a magnification of 200ϫ. ImmunoResearch Laboratories, Inc.) at room temperature for 1 hr. After four washes with PBS, Vectashield (Vector Laboratories, App Imaging) anti-fade Litter size and developmental index mounting medium was applied and sections were coverslipped and imaged.
For litter size at birth, the average numbers of pups in eight separate litters For controls, sections were directly incubated with secondary antibodies.
delivered from Col IV␣3/tumstatin Ϫ/Ϫ and age-matched wild-type mating In each group, the numbers of CD31, vWF, and ␤1/␤3 integrin-positive blood pairs were counted. For developmental index, the 6 week survival rates of vessels were counted in 10-30 fields at 200ϫ or 400ϫ magnifications in a the eight separate litters from both groups were calculated. blinded fashion.
Statistical analysis Proliferation assay
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